Magnesium aspartate (OTC)

Brand and Other Names:Maginex, Maginex DS
  • Print

Dosing & Uses


Dosage Forms & Strengths

tablet, enteric-coated

  • 61mg elemental Mg (615mg salt form)

granules for oral solution

  • 122mg elemental Mg/packet (1230mg salt form)

Magnesium Supplementation

19-30 years

  • Elemental magnesium
  • Males: 400mg/day
  • Females: 310mg/day
  • Pregnant females: 350mg/day
  • Lactation: 310mg/day

>30 years

  • Elemental magnesium
  • Males: 420mg/day
  • Females: 320mg/day
  • Pregnant females: 360mg/day
  • Lactation: 320mg/day

OTC Supplement

  • Salt form
  • 1 packet (dissolved in water or juice) or 2 tablets (1230 mg) up to 3 times daily

Dosage Forms & Strengths

(tablet, enteric-coated)

  • 61mg elemental Mg (615mg salt form)

(powder for oral solution)

  • 122mg elemental Mg/packet (1230mg salt form)

Magnesium Supplementation

Dietary reference intake for elemental magnesium varies in children according to age

<6 months: 30 mg/day

6-12 months: 75 mg/day

1-3 years: 80 mg/day

3-8 years: 130 mg/day

8-13 years: 240 mg/day

Adolescent boys 13-18 years: 410 mg/day

Adolescent girls

  • 13-18 years: 360 mg/day
  • Pregnant: 400 mg/day
  • Lactating: 360 mg/day

Adverse Effects

Frequency Not Defined



Gas formation






Hypermagnesemia may result with renal impairment

May aggravate existing heart disease

Caution in patients with myasthenia gravis or other neuromuscular disease

Accumulation of magnesium in renal impairment may lead to magnesium intoxication

Magnesium toxicity characterized by flushing, diaphoresis, hypotension, depressed deep tendon reflexes, muscle paralysis, weakness, hypothermia, circulatory collapse, and cardiac, CNS, or respiratory depression


Pregnancy & Lactation

Pregnancy Category: A; elemental magnesium dietary reference intake during pregnancy is 350-400 mg/day for adult women

Lactation: Distributed in breast milk, elemental magnesium dietary reference intake for breast feeding women is 310-360 mg/day for adult women

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.



Mechanism of Action

Cofactor for many enzymatic pathways involved in phosphate transfer reactions that use ATP and other nucleotides as substrates (eg, oxidative phosphorylation, oxygen radical reduction); involved in enzymatic reactions responsible for carbohydrate metabolism and protein synthesis

May play a role in reducing serum cholesterol and sodium/potassium ATPase responsible for neuromuscular functioning


Excretion: Urine



Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.